Universidad De Navarra
Universidad De Navarra is recorded as a service provider in 7 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 7 of 7 trials · Latest update first
A Phase 2b, Open-label, Multi-arm Clinical Trial of Selinexor Plus Low-dose Dexamethasone (Sd) in Patients with Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone (SVd) in Patients with Triple-class Refractory Multiple Myeloma
Sponsor Karyopharm Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase IIb, Monocentric, Non-Profit, Open-label Trial for the Intrathecal Administration of AAV9/AP4M1 for Hereditary Spastic Paraplegia Type 50 (SPG50)
Sponsor Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii
- Start (EU)
- Latest update
- Estimated end
- Not reported
Induction therapy with bortezomib, melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) vs. carfilzomib, lenalidomide and dexamethasone (KRd) with/without daratumumab, 18 cycles, followed by consolidation and maintenance with lenalidomide and daratumumab: a phase III, multicenter, randomized clinical trial for older adult patients between 65 and 80 years old, in good general health with newly-diagnosed multiple myeloma
Sponsor Fundacion PETHEMA
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 1b/2a Multicenter, Open-label, Dose Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination with Other Treatments in Subjects with Multiple Myeloma
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
A phase I/IIa clinical trial to assess feasibility, safety and antitumor activity of autologous SLAMF7 CAR-T cells in multiple myeloma
Sponsor Universitaetsklinikum Wuerzburg AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase IIb, Non-Profit, Open-label Trial for the Intrathecal Administration of AAV9/AP4M1 for Hereditary Spastic Paraplegia Type 50 (SPG50).
Sponsor Rigshospitalet
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Isatuximab in combination with Lenalidomide-Dexamethasone compared to Lenalidomide-Dexamethasone in elderly patients (aged ≥70 years) with newly diagnosed myeloma: a randomized phase II study (SGZ-2019-12650)
Sponsor Arbeitsgemeinschaft Medikamentoese Tumortherapie gGmbH
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Universidad De Navarra?
The 2026-10-09 snapshot links Universidad De Navarra to 7 distinct CTIS trials. Recorded services include Laboratory services, Cytokine analysis, immunophenotyping and MRD by flow cytometry, Genetic analysis-FISH/Karyotyping, Isolation of bone marrow myeloma cells for next generation flow (NGF). These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Universidad De Navarra?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Universidad De Navarra conducted?
The linked trials record locations in 8 countries, including Germany, Spain, Greece, Italy, Austria. These are trial locations, not confirmed office locations or countries where Universidad De Navarra delivered services.
What can this page tell me about Universidad De Navarra's trial experience?
Browse 7 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Universidad De Navarra. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Universidad De Navarra
- Universidad de Navarra